 |
|
Acute Disseminated Encephalomyelitis
An Update
Til Menge, MD;
Bernhard Hemmer, MD;
Stefan Nessler, MD;
Heinz Wiendl, MD;
Oliver Neuhaus, MD;
Hans-Peter Hartung, MD;
Bernd C. Kieseier, MD;
Olaf Stüve, MD, PhD
Arch Neurol. 2005;62:1673-1680.
Acute disseminated encephalomyelitis (ADEM) is a monophasic autoimmune demyelinating disease of the central nervous system that typically follows a febrile infection or a vaccination. Children are predominantly affected. A plethora of viral and bacterial pathogens and a number of vaccinations have been associated with ADEM. Experimental animal studies indicate that both primary and secondary autoimmune responses contribute to central nervous system inflammation and subsequent demyelination. The clinical diagnosis of ADEM is strongly suggested by a close temporal relationship between an infectious incident or an immunization and the onset of leukoencephalopathic neurological symptoms. Paraclinical tests may support the diagnosis. Particularly helpful are acute signs of newly developed extensive, multifocal, subcortical white matter abnormalities on magnetic resonance images of the brain. The cerebrospinal fluid may disclose a mild lymphocytic pleocytosis and elevated albumin levels. Oligoclonal bands are not always present in ADEM and, if so, may be transient. The major differential diagnosis of ADEM is multiple sclerosis. Treatment options for ADEM consist of anti-inflammatory and immunosuppressive agents. In general, the disease is self-limiting and the prognostic outcome favorable. In the absence of widely accepted clinical or paraclinical diagnostic guidelines, a number of recently conducted observational case series have substantially broadened our understanding about the clinical phenotype, diagnosis, and prognosis of ADEM.
Author Affiliations: Department of Neurology, University of San Francisco, San Francisco, Calif (Dr Menge); Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany (Drs Hemmer, Nessler, Neuhaus, Hartung, Kieseier, and Stüve); Hertie Institute for Clinical Brain Research, Department of Neurology, Eberhard-Karls-University, Tübingen, Germany (Dr Wiendl); Department of Neurology, University of Texas Southwestern Medical Center, and Neurology Section, Medical Service, VA North Texas Health Care System, Dallas (Dr Stüve).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood
Mikaeloff et al.
Neurology 2009;72:873-880.
ABSTRACT
| FULL TEXT
Prognostic factors after a first attack of inflammatory CNS demyelination in children
Neuteboom et al.
Neurology 2008;71:967-973.
ABSTRACT
| FULL TEXT
ATM--OMG!
Ross
Am. J. Neuroradiol. 2008;29:618-618.
FULL TEXT
Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
de Seze et al.
Arch Neurol 2007;64:1426-1432.
ABSTRACT
| FULL TEXT
Case 24-2007 -- A 20-Year-Old Pregnant Woman with Altered Mental Status
Cole et al.
NEJM 2007;357:589-600.
FULL TEXT
Acute Disseminated Encephalomyelitis Initially Diagnosed as Dissociative Disorder
Corrales-Arroyo and Ortiz-Pascual
J. Neuropsychiatry Clin. Neurosi. 2007;19:339-340.
FULL TEXT
Acute disseminated encephalomyelitis
Tenembaum et al.
Neurology 2007;68:S23-S36.
ABSTRACT
| FULL TEXT
High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma
Kiewe et al.
Neuro Oncol Duke 2007;9:96-102.
ABSTRACT
| FULL TEXT
Anti-Viral T-Cell Immunity + Anti-CNS Autoantibody = A Model for Human Acute Disseminated Encephalomyelitis or Multiple Sclerosis Relapse?
Sobel
Am. J. Pathol. 2007;170:436-438.
FULL TEXT
|
